Publication bias and outcome reporting bias: Agomelatine as a case example

Journal of Psychosocial Nursing and Mental Health Services

Volumn 49, Issue 9, 2011, Pages 11-14

  Howland, Robert H ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 80053076207     PISSN: 02793695     EISSN: None     Source Type: Journal    
DOI: 10.3928/02793695-20110809-01     Document Type: Article

References (11)

1. Hickie, I.B., & Rogers, N.L. (2011). Novel melatonin-based therapies: Potential advances in the treatment of major depression. Lancet. Advance online publication doi:10.1016/S0140-6736(11)60095-0
2. Howland, R.H. (2007). Agomelatine: A novel atypical antidepressant. Journal of Psychosocial Nursing and Mental Health Services, 45(12), 13-17
3. Howland, R.H. (2009). Critical appraisal and update on the clinical utility of agomelatine, a melatonergic agonist, for the treatment of major depressive disease in adults. Neuropsychiatric Disease and Treatment, 5, 563-576
4. Howland, R.H. (2011a). A risk-benefit assessment of agomelatine in the treatment of major depression. Drug Safety, 34, 709-731
5. Howland, R.H. (2011b). What you see depends on where you're looking and how you look at it: Publication bias and outcome reporting bias. Journal of Psychosocial Nursing and Mental Health Services, 49(8), 13-15
6. Kasper, S., Hajak, G., Wulff, K., Hoogendijk, W.J., Montejo, A.L., Smeraldi, E. Baylé, F.J. (2010). Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: A randomized double-blind comparison with sertraline. Journal of Clinical Psychiatry, 71, 109-120
7. Kennedy, S.H., Rizvi, S., Fulton, K., & Rasmussen, J. (2008). A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR. Journal of Clinical Psychopharmacology, 28, 329-333
8. Lemoine, P., Guilleminault, C., & Alvarez, E. (2007). Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: Randomized double-blind comparison with venlafaxine. Journal of Clinical Psychiatry, 68, 1723-1732
9. Montejo, A.L., Prieto, N., Terleira, A., Matias, J., Alonso, S., Paniagua, G. Portolés, A. (2010). Better sexual acceptability of agomelatine (25 and 50 mg) compared with paroxetine (20 mg) in healthy male volunteers: An 8-week placebo-controlled study using the PRSEXDQSALSEX scale. Journal of Psychopharmacology, 24, 111-120
10. Montgomery, S.A., & Kasper, S. (2007). Severe depression and antide-pressants: Focus on a pooled analysis of placebo-controlled studies on agomelatine. International Clinical Psychopharmacology, 22, 283-291
11. Rouillon, F. (2006). Efficacy and tolerance profile of agomelatine and practical use in depressed patients. International Clinical Psychopharmacology, 21(Suppl. 1), S31-S35